The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Cited by
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Duma, N., Santana-Davila, R., & Molina, J. R. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.013 · Cited by 2,184
Lei, X., Lei, Y., Li, J.-K., Du, W.-X., Li, R.-G., Yang, J., Li, J., Li, F., & Tan, H.-B. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.009 · Cited by 1,470
Wnt/beta-catenin pathway: modulating anticancer immune response
Pai, S. G., Carneiro, B. A., Mota, J. M., Costa, R., Leite, C. A., Barroso-Sousa, R., Kaplan, J. B., Chae, Y. K., & Giles, F. J. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0471-6 · Cited by 703
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
Trebeschi, S., Drago, S. G., Birkbak, N. J., Kurilova, I., Cǎlin, A. M., Delli Pizzi, A., Lalezari, F., Lambregts, D. M. J., Rohaan, M. W., Parmar, C., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz108 · Cited by 566
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
Camidge, D. R., Doebele, R. C., & Kerr, K. M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0173-9 · Cited by 511
Duan, X., Chan, C., Guo, N., Han, W., Weichselbaum, R. R., & Lin, W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b09538 · Cited by 458
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
Effects of exosomes on pre-metastatic niche formation in tumors
Guo, Y., Ji, X., Liu, J., Fan, D., Zhou, Q., Chen, C., Wang, W., Wang, G., Wang, H., Yuan, W., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0995-1 · Cited by 401
Steven, A., Fisher, S. A., & Robinson, B. W. (2016) · Respirology · doi:10.1111/resp.12789 · Cited by 338
PD-1 and its ligands are important immune checkpoints in cancer
Dong, Y., Sun, Q., & Zhang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.13895 · Cited by 334
Biomarkers of response to PD-1/PD-L1 inhibition
Maleki Vareki, S., Garrigós, C., & Duran, I. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.06.001 · Cited by 318
Nicolazzo, C., Raimondi, C., Mancini, M., Caponnetto, S., Gradilone, A., Gandini, O., Mastromartino, M., del Bene, G., Prete, A., Longo, F., et al. (2016) · Scientific Reports · doi:10.1038/srep31726 · Cited by 281
Cancer transcriptome profiling at the juncture of clinical translation
Cieślik, M., & Chinnaiyan, A. M. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.96 · Cited by 269
Jia, Y., Li, X., Jiang, T., Zhao, S., Zhao, C., Zhang, L., Liu, X., Shi, J., Qiao, M., Luo, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32191 · Cited by 164
Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Journal of Immunology Research · doi:10.1155/2021/6661406 · Cited by 136
Sha, L., Osinski, B. L., Ho, I. Y., Tan, T. L., Willis, C., Weiss, H., Beaubier, N., Mahon, B. M., Taxter, T. J., & Yip, S. S. F. (2019) · Journal of Pathology Informatics · doi:10.4103/jpi.jpi_24_19 · Cited by 130
Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115
Jiang, J., Ding, Y., Wu, M., Lyu, X., Wang, H., Chen, Y., Wang, H., & Teng, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01765 · Cited by 52
“Over the past years, the applications of PD-1/PD-L1 checkpoint blockades in cancer have revolutionized oncology (28, 29).”
BackgroundJennewein, L., Bartsch, G., Gust, K., Kvasnicka, H., Haferkamp, A., Blaheta, R., Mittelbronn, M., Harter, P., & Mani, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8597 · Cited by 27
van Duijn, A., Willemsen, K. J., van Uden, N. O. P., Hoyng, L., Erades, S., Koster, J., Luiten, R. M., & Bakker, W. J. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-03007-1 · Cited by 24
Role of immunotherapy in chondrosarcoma: A case report and review of the literature
Cohen-Nowak, A. J., Dressler, D. B., Rock, A., Mojica, K., Woo, D., Zuckerman, L. M., Chow, W., & Agulnik, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231199877 · Cited by 16
Metadata
- Authors
- Meng, X., Huang, Z., Teng, F., Xing, L., & Yu, J.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 41
- Issue
- 10
- Pages
- 868-876
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2187430385
- Cited by
- 401
- References
- 65
- FWCI
- 19.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.